---
title: "EU Seeks Views on Sanofi's Concessions to End Competition Probe — Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292063120.md"
description: "The European Commission is seeking feedback on Sanofi's proposed concessions to resolve an antitrust investigation into alleged disparagement of a rival flu vaccine. Sanofi offered commitments, valid until March 2030, including acknowledging independent vaccine assessments and avoiding negative claims about CSL Seqirus's Fluad. The EU set an August 21 deadline for comments. Sanofi maintains it has acted in full compliance with competition laws."
datetime: "2026-07-08T11:46:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292063120.md)
  - [en](https://longbridge.com/en/news/292063120.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292063120.md)
generator: "portal-rs"
---

# EU Seeks Views on Sanofi's Concessions to End Competition Probe — Update

By Edith Hancock

The European Commission is seeking feedback on a package of concessions that healthcare group Sanofi has offered to end a competition investigation into the company. 

It comes after the European Union's executive arm started investigating Sanofi in June over concerns it unfairly pursued a campaign to disparage a rival flu vaccine by portraying it as inferior to its own Efluelda. Sanofi said in September 2025 the commission raided its premises over antitrust concerns. 

The commission said that Sanofi offered to publish statements on its French and German websites acknowledging assessments of the vaccines carried out by the European Centre for Disease Prevention and Control and national immunisation technical advisory groups, and to avoid portraying rival CSL Seqirus's drug Fluad negatively, or claiming that Efluelda is safer or more effective. The company's commitments would be in effect until March 2030, the EU said. 

"Sanofi remains confident that it has acted, and continues to act, in full compliance with all applicable laws and regulations, including competition law," a company spokesperson said, adding that Sanofi will continue to cooperate with the commission. 

The regulator set an Aug. 21 deadline to receive feedback on the offer. 

Write to Edith Hancock at edith.hancock@wsj.com 

(END) Dow Jones Newswires

July 08, 2026 07:32 ET (11:32 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### Related Stocks

- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [CSLLY.US](https://longbridge.com/en/quote/CSLLY.US.md)
- [CSL.AU](https://longbridge.com/en/quote/CSL.AU.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [Sanofi Faces EU Probe With Fines Possibly Reaching 10%](https://longbridge.com/en/news/290995146.md)
- [CSL Swings to $2.58 Billion Annual Loss on Write-Downs](https://longbridge.com/en/news/296152819.md)
- [Kimberly-Clark files with European antitrust regulator for review of Kenvue deal](https://longbridge.com/en/news/297082129.md)
- [Did Nexviazyme’s Baby-COMET Win and M1Pram Shift Just Reframe Sanofi’s (ENXTPA:SAN) Rare-Disease Focus?](https://longbridge.com/en/news/292092971.md)
- [Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D](https://longbridge.com/en/news/294405008.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**